Several analysts have recently updated their ratings and price targets for Inogen (NASDAQ: INGN):

  • 4/14/2018 – Inogen was given a new $145.00 price target on by analysts at Piper Jaffray. They now have a “buy” rating on the stock.
  • 4/6/2018 – Inogen was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 4/6/2018 – Inogen was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 3/27/2018 – Inogen had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $150.00 price target on the stock.
  • 3/9/2018 – Inogen was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 3/5/2018 – Inogen was downgraded by analysts at Zacks Investment Research from a “strong-buy” rating to a “hold” rating. According to Zacks, “Inogen ended the fourth quarter of 2017 on a positive note, with earnings and revenues beating the Zacks Consensus Estimate. Promising business-to-business and direct-to-consumer sales growth is encouraging. The company expects direct-to-consumer sales to be its fastest growing channel, domestic business-to-business sales to have a solid growth rate. Inogen will continue to focus on the European markets. Raised revenue guidance for 2018 also instills confidence. On the flip side, declining rental revenues is a concern. Moreover, the international business-to-business sales declined lately. Adding to the woes, the company saw diminishing gross margin and a rise in operating expenses, driven by gradually increasing research and development spending. Stiff competition in the niche space is likely to mar prospects.”
  • 3/2/2018 – Inogen was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 2/28/2018 – Inogen had its price target raised by analysts at Needham & Company LLC from $125.00 to $150.00. They now have a “strong-buy” rating on the stock.
  • 2/20/2018 – Inogen was upgraded by analysts at Piper Jaffray from a “neutral” rating to an “overweight” rating.
  • 2/19/2018 – Inogen was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $135.00 price target on the stock. According to Zacks, “Over the last year Inogen has outperformed the broader industry in terms of price. The company expects direct-to-consumer sales to be its fastest growing channel, followed by domestic business-to-business sales in the coming quarters, with solid focus in Europe. The company is also upbeat about its full-year 2017 revenue guidance. Solid domestic and international business-to-business sales has been boosting Inogen. The company took a series of strategic initiatives to strengthen its product offerings and market position. On the flip side, declining rental revenues raise concern. Moreover, since the company generates a significant portion of its revenues from the international market, volatile foreign exchange rate will continue to raise concern. Low POC adoption, intensifying competition, reimbursement cuts and foreign exchange headwinds are other major concerns. Reimbursement cuts and foreign exchange headwinds are other major concerns.”

Shares of NASDAQ INGN traded up $0.81 during trading hours on Tuesday, reaching $140.24. 15,894 shares of the stock were exchanged, compared to its average volume of 140,855. The firm has a market cap of $2,947.02, a P/E ratio of 107.05, a price-to-earnings-growth ratio of 3.86 and a beta of 1.03. Inogen has a 52 week low of $75.38 and a 52 week high of $143.00.

How to Become a New Pot Stock Millionaire

Inogen (NASDAQ:INGN) last announced its earnings results on Tuesday, February 27th. The medical technology company reported $0.31 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.10. The company had revenue of $63.79 million for the quarter, compared to analyst estimates of $62.01 million. Inogen had a return on equity of 13.47% and a net margin of 8.42%. research analysts predict that Inogen will post 1.6 earnings per share for the current fiscal year.

In other news, CFO Alison Bauerlein sold 11,718 shares of the stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $115.87, for a total transaction of $1,357,764.66. Following the transaction, the chief financial officer now owns 11,718 shares in the company, valued at $1,357,764.66. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Brenton Taylor sold 15,000 shares of the stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $117.47, for a total value of $1,762,050.00. Following the transaction, the executive vice president now owns 38,982 shares in the company, valued at approximately $4,579,215.54. The disclosure for this sale can be found here. In the last quarter, insiders have sold 112,218 shares of company stock worth $13,570,316. 5.29% of the stock is owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of INGN. Lenox Wealth Advisors Inc. bought a new position in Inogen during the 4th quarter worth $100,000. Steward Partners Investment Advisory LLC increased its stake in Inogen by 1,000.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,100 shares of the medical technology company’s stock worth $130,000 after acquiring an additional 1,000 shares during the period. Simplex Trading LLC bought a new position in Inogen during the 4th quarter worth $153,000. LS Investment Advisors LLC increased its stake in Inogen by 138.6% during the 4th quarter. LS Investment Advisors LLC now owns 1,515 shares of the medical technology company’s stock worth $180,000 after acquiring an additional 880 shares during the period. Finally, Everence Capital Management Inc. bought a new position in Inogen during the 4th quarter worth $208,000. Hedge funds and other institutional investors own 98.97% of the company’s stock.

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.